title: Interferon α may be back on track to treat acute myeloid leukemia.
abstract: Our own experience and a thorough literature review suggest that interferon α (IFNα) should be reconsidered for the treatment of acute myeloid leukemia patients. Most likely, the success of such treatment depends on the achievement of high serum levels of IFNα for several months, which can be obtained by using pegylated IFNα.
authors.affiliation: Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium ; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium.
authors.forename: Evelien L J M
authors.initials: EL
authors.lastname: Smits
authors.forename: Sébastien
authors.initials: S
authors.lastname: Anguille
authors.forename: Zwi N
authors.initials: ZN
authors.lastname: Berneman
keywords: acute myeloid leukemia; immunotherapy; interferon; pegylation